Carlsmed, Inc. (NASDAQ:CARL – Get Free Report)’s share price traded up 7.8% during trading on Monday. The company traded as high as $18.22 and last traded at $18.4550. Approximately 43,340 shares were traded during mid-day trading, a decline of 68% from the average daily volume of 135,142 shares. The stock had previously closed at $17.12.
Analysts Set New Price Targets
CARL has been the subject of several recent analyst reports. BTIG Research lifted their price objective on shares of Carlsmed from $24.00 to $26.00 and gave the stock a “buy” rating in a research note on Wednesday, November 11th. Needham & Company LLC raised their target price on shares of Carlsmed from $17.00 to $22.00 and gave the stock a “buy” rating in a report on Wednesday, November 11th. Truist Financial lifted their price target on shares of Carlsmed from $20.00 to $23.00 and gave the stock a “buy” rating in a research note on Wednesday, November 11th. Wall Street Zen raised shares of Carlsmed from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Carlsmed in a research note on Wednesday, November 4th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $22.00.
Check Out Our Latest Research Report on CARL
Carlsmed Stock Up 1.6%
Carlsmed (NASDAQ:CARL – Get Free Report) last issued its earnings results on Tuesday, November 10th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.08. Carlsmed had a negative net margin of 55.82% and a negative return on equity of 42.42%. The firm had revenue of $21.55 million during the quarter. As a group, analysts anticipate that Carlsmed, Inc. will post -1.53 EPS for the current year.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of the stock. Deutsche Bank AG acquired a new position in Carlsmed in the second quarter valued at approximately $106,000. Bank of America Corp DE acquired a new stake in Carlsmed during the second quarter worth approximately $108,000. Entropy Technologies LP acquired a new stake in Carlsmed during the 3rd quarter worth $160,000. Alpine Woods Capital Investors LLC purchased a new stake in shares of Carlsmed in the 2nd quarter valued at about $161,000. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Carlsmed in the 2nd quarter valued at about $181,000.
About Carlsmed
Carlsmed, Inc. is a medical technology company focused on personalized solutions for spine surgery. Its technology uses patient-specific planning and implant design to help surgeons plan spinal-fusion procedures. The company’s products include aprevo®, a line of patient-specific interbody implants made using 3D printing. Carlsmed’s platform is designed to use a patient’s imaging and surgical plan to tailor implant geometry and support alignment goals. Founded in 2018 and based in Carlsbad, California, Carlsmed serves the U.S. market.
Recommended Stories
- Five stocks we like better than Carlsmed
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Carlsmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carlsmed and related companies with MarketBeat.com's FREE daily email newsletter.
